BIOMAT Database Logo BIOMAT Database Logo

Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. 2004

Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
Biological Research Laboratories, Sankyo Co., Ltd, 2-58 Hiromachi 1-chome, Shinagawa-ku, Tokyo 140-8710, Japan. tekoga@sankyo.co.jp

OBJECTIVE The antimycobacterial activities of RS-112997, RS-124922 and RS-118641, three capuramycin analogues that inhibit phospho-N-acetylmuramyl-pentapeptide translocase, were tested against clinical isolates of Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare. RESULTS MICs were determined by the broth microdilution method using a modified Middlebrook 7H9 broth. RS-118641 was the most potent compound overall. The MIC50/90 (mg/L) results for RS-118641 were: M. tuberculosis, 1/2; multidrug-resistant (MDR) M. tuberculosis, 0.5/2; M. avium, 4/8; and M. intracellulare, 0.06/0.5. No statistically significant differences in MIC distributions were observed between non-MDR and MDR M. tuberculosis for any of the capuramycin analogues tested. In order to evaluate the therapeutic efficacy of RS-112997 and RS-124922 in a murine lung model of tuberculosis, both compounds were administered intranasally at 0.1 or 1 mg/mouse/day for 12 days. The mycobacterial load in the lungs was significantly lower in all treatment groups than in the untreated controls. Additional experiments were performed to evaluate the therapeutic efficacy of the three compounds against the M. intracellulare infection in mice. All compounds were administered intranasally at 0.1 mg/mouse/day for 21 days. The mycobacterial load in the lungs was significantly lower in all treatment groups than in the untreated controls. CONCLUSIONS These results suggest that capuramycin analogues exhibit strong antimycobacterial potential and should be considered for further evaluation in the treatment of M. tuberculosis and M. avium-M. intracellulare complex infections in humans.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009162 Mycobacterium avium A bacterium causing tuberculosis in domestic fowl and other birds. In pigs, it may cause localized and sometimes disseminated disease. The organism occurs occasionally in sheep and cattle. It should be distinguished from the M. avium complex, which infects primarily humans.
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005260 Female Females
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000617 Aminoglycosides Glycosylated compounds in which there is an amino substituent on the glycoside. Some of them are clinically important ANTIBIOTICS. Aminoglycoside
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular

Related Publications

Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
In vitro activity of ciprofloxacin and ofloxacin against the Mycobacterium avium-intracellulare complex.
May 1987, Diagnostic microbiology and infectious disease,
Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
In Vitro Activity of 3-Triazeneindoles against Mycobacterium tuberculosis and Mycobacterium avium.
October 2016, Antimicrobial agents and chemotherapy,
Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
Thiacetazone: in vitro activity against Mycobacterium avium and M. tuberculosis.
December 1990, Tubercle,
Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
In vitro activities of 2,2'-bipyridyl analogues against Mycobacterium avium and M. tuberculosis.
April 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease,
Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
Monoclonal antibodies against Mycobacterium avium/intracellulare.
July 1988, The Indian journal of medical research,
Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.
March 1990, The American review of respiratory disease,
Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare.
November 1992, Infection and immunity,
Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis.
December 1993, Antimicrobial agents and chemotherapy,
Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
In vitro and in vivo chemotherapeutic activity of rifabutin (LM 427) on Mycobacterium avium-intracellulare complex.
March 1987, Bulletin of the Chest Disease Research Institute, Kyoto University,
Tetsufumi Koga, and Takashi Fukuoka, and Norio Doi, and Tamako Harasaki, and Harumi Inoue, and Hitoshi Hotoda, and Masayo Kakuta, and Yasunori Muramatsu, and Naotoshi Yamamura, and Misa Hoshi, and Takashi Hirota
[In vitro evaluation of the antibacterial activity of nemonoxacin against Mycobacterium tuberculosis, Mycobacterium intracellulare and Mycobacterium abscessus].
December 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
Copied contents to your clipboard!